Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for a clinical-stage biotech like Pluri Inc (PLUR) can run hundreds of pages, packed with scientific jargon on 3-D cell expansion, placental-derived therapies, and cultivated-meat joint ventures. Finding how much cash is left for trials, or spotting when executives file Form 4s before a financing round, is tedious.
Stock Titan solves the problem. Our AI reads every Pluri annual report 10-K, each quarterly earnings report 10-Q filing, and every 8-K material event within minutes of hitting EDGAR. It then produces plain-English summaries, highlights clinical milestones, and flags contract-development (CDMO) revenue trends so you can understand Pluri SEC documents with AI, not a microscope. You’ll also get real-time alerts on Pluri insider trading Form 4 transactions and a dashboard that links each disclosure to the exact page where the data lives.
Whether you’re monitoring a shelf registration that funds the next immunotherapy study, tracking Pluri executive stock transactions Form 4, or comparing cytokine-release safety data across periods, the entire story sits here:
- Pluri annual report 10-K simplified – R&D spend, GMP facility capacity, key risk factors
- Pluri quarterly earnings report 10-Q filing – cash runway, partnership revenue
- Pluri proxy statement executive compensation – incentive alignment for trial success
- Pluri 8-K material events explained – collaboration announcements and FDA feedback
- Pluri Form 4 insider transactions real-time – who’s buying before pivotal data
Get Pluri SEC filings explained simply, perform Pluri earnings report filing analysis in seconds, and evaluate dilution risk, cultivated-meat commercialization timelines, and more before the market digests the news. Complex filings, simplified.
Lennox International Inc. (LII) – Form 144 filing discloses that John W. Norris III intends to sell 3,190 shares of the company’s common stock. The planned transaction, to be executed through Morgan Stanley Smith Barney LLC, carries an estimated aggregate market value of $1.92 million based on the quoted market price at the time of filing. The shares represent roughly 0.009% of the 35.48 million shares outstanding, signalling a limited dilution impact.
The shares were originally received as a gift on 23 Jul 2009; thus, the filing satisfies Rule 144’s disclosure requirement for the resale of restricted or control securities. An accompanying table shows that the same holder already sold an identical 3,190-share block on 1 Jul 2025 for gross proceeds of $1.91 million, indicating continued disposition of gifted shares. The expected sale date for the new block is 3 Jul 2025 on the NYSE.
Because the filing is a notice of intent—not a confirmation of execution—and the volume is immaterial relative to total shares, the market impact is likely minimal. Nonetheless, recurring insider sales can attract investor attention regarding insider sentiment.
Offering overview: Morgan Stanley Finance LLC, guaranteed by Morgan Stanley (“MS”), is marketing five-year “Trigger PLUS” structured notes that settle on August 5, 2030. The notes are linked to the worst-performing of three U.S. equity benchmarks -- the S&P 500 (SPX), Nasdaq-100 (NDX) and Russell 2000 (RTY).
- Upside participation: Final payment equals principal plus 160%–175% of any positive performance of the worst index.
- Downside buffer: Principal is repaid in full as long as the worst index has not fallen more than 35 percent (i.e., it remains at or above 65 percent of its initial level) on the single observation date of July 31, 2030.
- Full downside exposure below the threshold: If that 65 percent trigger is breached, repayment equals principal multiplied by the worst index’s percentage return, generating dollar-for-dollar losses and potentially zero recovery.
- No interim coupons, no early call: Investors receive no periodic interest and their return depends solely on the final index levels.
- Credit & liquidity considerations: All cash flows rely on Morgan Stanley’s credit; the notes will not be listed, and MS expects limited secondary trading. The indicative estimated value is $943.40 versus the assumed $1,000 issue price, reflecting embedded fees and hedging costs.
- Key dates: Pricing - July 31, 2025 | Observation - July 31, 2030 | Maturity - August 5, 2030
- CUSIP: 61778NAZ4 | Registration Nos.: 333-275587 / 333-275587-01
Investor take-away: The structure offers leveraged upside and a 35% buffer, but embeds significant risks: (i) worst-of design magnifies downside probability, (ii) principal is unprotected below the trigger, (iii) valuation is below par at issuance, (iv) tax treatment is uncertain, and (v) investors assume MS credit and secondary-market liquidity risk.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
What is the primary focus of Pluri Inc?
How does Pluri Inc generate its revenue?
What sets Pluri Inc's technology platform apart?
In which industries does Pluri Inc operate?
What are some of the strategic collaborations of Pluri Inc?
How does Pluri Inc ensure product quality?
What role does Pluri Inc play in the foodtech and agtech sectors?
What is the significance of Pluri Inc’s CDMO services?
